{
  "data": {
    "id": "stat_VDR1F8EMJGEPWERWT3QCQ6PRPX",
    "url": "https://statorigin.org/stat/stat_VDR1F8EMJGEPWERWT3QCQ6PRPX",
    "indicator": {
      "slug": "ctgov-gene-phase-3-trials",
      "name": "Phase 3 gene editing trials",
      "definition": "Count of interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 or Phase 2/3, any start date."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "period": {
      "start": "2026-09-27",
      "end": "2026-09-27",
      "type": "point"
    },
    "value": 11,
    "value_text": "11 studies",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
      "org_short_name": "ClinicalTrials.gov",
      "org_url": "https://clinicaltrials.gov",
      "org_tier": 1,
      "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27",
      "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId",
      "document_type": "dataset",
      "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27.",
      "quote": "{\"totalCount\":11,\"studies\":[",
      "published_date": null,
      "accessed_at": "2026-09-27",
      "license": "public-domain",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "pipeline:ctgov-api-totalcount-verified",
    "verified_at": "2026-09-27T12:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": "stat_1KDHS6DJAVFHR77PZEPVCFFKMA",
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR%20OR%20Cas9%20OR%20Cas12%20OR%20%22base%20editing%22%20OR%20%22base%20editor%22%20OR%20%22prime%20editing%22%20OR%20%22gene%20editing%22%20OR%20%22genome%20editing%22%20OR%20%22zinc%20finger%20nuclease%22%20OR%20TALEN%20OR%20exagamglogene%20OR%20NTLA-2001%20OR%20NTLA-2002%20OR%20nexiguran%20OR%20lonvoguran%20OR%20VERVE-101%20OR%20VERVE-102%20OR%20BEAM-101%20OR%20BEAM-302%20OR%20EBT-101%20OR%20EDIT-101%20OR%20CTX310%20OR%20%22epigenetic%20editing%22%20OR%20CTX320%20OR%20YOLT-101%20OR%20YOLT-201%20OR%20ART001%20OR%20CS-101&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BPhase%5DPHASE3&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_VDR1F8EMJGEPWERWT3QCQ6PRPX",
      "bibtex": "@misc{clinicaltrialsgo2026ctgovq6prpx,\n  author       = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n  title        = {ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_VDR1F8EMJGEPWERWT3QCQ6PRPX},\n  note         = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=CRISPR\\%20OR\\%20Cas9\\%20OR\\%20Cas12\\%20OR\\%20\\%22base\\%20editing\\%22\\%20OR\\%20\\%22base\\%20editor\\%22\\%20OR\\%20\\%22prime\\%20editing\\%22\\%20OR\\%20\\%22gene\\%20editing\\%22\\%20OR\\%20\\%22genome\\%20editing\\%22\\%20OR\\%20\\%22zinc\\%20finger\\%20nuclease\\%22\\%20OR\\%20TALEN\\%20OR\\%20exagamglogene\\%20OR\\%20NTLA-2001\\%20OR\\%20NTLA-2002\\%20OR\\%20nexiguran\\%20OR\\%20lonvoguran\\%20OR\\%20VERVE-101\\%20OR\\%20VERVE-102\\%20OR\\%20BEAM-101\\%20OR\\%20BEAM-302\\%20OR\\%20EBT-101\\%20OR\\%20EDIT-101\\%20OR\\%20CTX310\\%20OR\\%20\\%22epigenetic\\%20editing\\%22\\%20OR\\%20CTX320\\%20OR\\%20YOLT-101\\%20OR\\%20YOLT-201\\%20OR\\%20ART001\\%20OR\\%20CS-101\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BPhase\\%5DPHASE3\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}"
    },
    "updated_at": "2026-09-27T01:11:36.992Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}